Overexpression of lysine specific demethylase 1 predicts worse prognosis in primary hepatocellular carcinoma patients

World Journal of Gastroenterology

Volumn 18, Issue 45, 2012, Pages 6651-6656

  Zhao, Ze Kun ^a   Yu, Hai Feng ^b   Wang, Dao Rong ^c   Dong, Ping ^a   Chen, Lei ^a   Wu, Wen Guang ^a   Ding, Wen Jun ^a   Liu, Ying Bin ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b YIXING PEOPLE S HOSPITAL   (China)

^c NORTHERN JIANGSU PEOPLE S HOSPITAL   (China)

Author keywords

Hepatocellular carcinoma; Lysine specific demethylase 1; Prognosis; Tumor progression

Indexed keywords

HISTONE DEMETHYLASE; LYSINE SPECIFIC DEMETHYLASE 1; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; WESTERN BLOTTING;

EID: 84873919440     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i45.6651     Document Type: Article

References (26)

1. Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma--epidemiological trends and risk factors. Dig Dis 2009; 27: 80-92
2. Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 2001; 313: 15-19
3. Blum HE, Spangenberg HC. Hepatocellular carcinoma: an update. Arch Iran Med 2007; 10: 361-371
4. Wang J, Scully K, Zhu X, Cai L, Zhang J, Prefontaine GG, Krones A, Ohgi KA, Zhu P, Garcia-Bassets I, Liu F, Taylor H, Lozach J, Jayes FL, Korach KS, Glass CK, Fu XD, Rosenfeld MG. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature 2007; 446: 882-887
5. Scoumanne A, Chen X. The lysine-specific demethylase 1 is required for cell proliferation in both p53-dependent and-independent manners. J Biol Chem 2007; 282: 15471-15475
6. Lim S, Janzer A, Becker A, Zimmer A, Schüle R, Buettner R, Kirfel J. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 2010; 31: 512-520
7. Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, Field HI, Neal DE, Yamaue H, Ponder BA, Nakamura Y, Hamamoto R. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 2011; 128: 574-586
8. Chen PP, Li WJ, Wang Y, Zhao S, Li DY, Feng LY, Shi XL, Koeffler HP, Tong XJ, Xie D. Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS One 2007; 2: e534
9. Guo X, Xiong L, Zou L, Zhao J. Upregulation of bone morphogenetic protein 4 is associated with poor prognosis in patients with hepatocellular carcinoma. Pathol Oncol Res 2012; 18: 635-640
10. Schmilovitz-Weiss H, Tobar A, Halpern M, Levy I, Shabtai E, Ben-Ari Z. Tissue expression of squamous cellular carcinoma antigen and Ki67 in hepatocellular carcinoma-correlation with prognosis: a historical prospective study. Diagn Pathol 2011; 6: 121
11. Hong H, Patonay B, Finley J. Unusual reticulin staining pattern in well-differentiated hepatocellular carcinoma. Diagn Pathol 2011; 6: 15
12. Müller P, Crofts JD, Newman BS, Bridgewater LC, Lin CY, Gustafsson JA, Ström A. SOX9 mediates the retinoic acidinduced HES-1 gene expression in human breast cancer cells. Breast Cancer Res Treat 2010; 120: 317-326
13. Lü B, Fang Y, Xu J, Wang L, Xu F, Xu E, Huang Q, Lai M. Analysis of SOX9 expression in colorectal cancer. Am J Clin Pathol 2008; 130: 897-904
14. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT, Luk JM. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009; 115: 4576-4585
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) Method. Methods 2001; 25: 402-408
16. Piperi C, Vlastos F, Farmaki E, Martinet N, Papavassiliou AG. Epigenetic effects of lung cancer predisposing factors impact on clinical diagnosis and prognosis. J Cell Mol Med 2008; 12: 1495-1501
17. Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, Wang Q, Chia D, Goodglick L, Kurdistani SK. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009; 174: 1619-1628
18. Shi Y. Histone lysine demethylases: emerging roles in development, physiology and disease. Nat Rev Genet 2007; 8: 829-833
19. Risch A, Plass C. Lung cancer epigenetics and genetics. Int J Cancer 2008; 123: 1-7
20. Ueda R, Suzuki T, Mino K, Tsumoto H, Nakagawa H, Hasegawa M, Sasaki R, Mizukami T, Miyata N. Identification of cellactive lysine specific demethylase 1-selective inhibitors. J Am Chem Soc 2009; 131: 17536-17537
21. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004; 119: 941-953
22. Lim S, Metzger E, Schüle R, Kirfel J, Buettner R. Epigenetic regulation of cancer growth by histone demethylases. Int J Cancer 2010; 127: 1991-1998
23. Zhu Q, Huang Y, Marton LJ, Woster PM, Davidson NE, Casero RA. Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. Amino Acids 2012; 42: 887-898
24. Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, Ora I, Pajtler K, Klein-Hitpass L, Kuhfittig-Kulle S, Metzger E, Schüle R, Eggert A, Buettner R, Kirfel J. Lysinespecific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res 2009; 69: 2065-2071
25. Suikki HE, Kujala PM, Tammela TL, van Weerden WM, Vessella RL, Visakorpi T. Genetic alterations and changes in expression of histone demethylases in prostate cancer. Prostate 2010; 70: 889-898
26. Lv T, Yuan D, Miao X, Lv Y, Zhan P, Shen X, Song Y. Overexpression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS One 2012; 7: e35065